Our new #mycetoma drug fosravuconazole and an antibiotic developed by GARDP are examples of non-profits delivering much-needed treatments where there is no financial incentive for most pharmaceutical firms to act. Non-profit drug development works. (2/4)

Fosravuconazole was first developed by Eisai for onychomycosis, then tested by DNDi & partners as a treatment for #mycetoma. 'We call it repurposing: taking a drug that was developed for one indication... that we then repurpose for another,' says Rachel Cohen, DNDi policy and access advisor. (3/4)